BTYNB

Name: BTYNB
Brand: MedChemExpress
SKU: HY-124447
Rating: 4.5 (1 reviews)

Cat. No.: HY-124447 Purity: 98.0%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

BTYNB is a structure-specific nucleic acid binder and IGF2BP1 inhibitor (with an IC₅₀ of 5 μM against hBTYNB). BTYNB disrupts the IGF2BP1-RNA interaction and blocks its binding to oncogenic mRNAs such as c-Myc, MDM2, PD-L1. BTYNB completely blocks the INHBA-Smad2/3 pathway, disrupts the MYCN/IGF2BP1 loop, and thereby induces apoptosis and cell cycle arrest, effectively inhibiting the proliferation and survival of cancer cells. In addition, BTYNB acts as an immune activator and tumor microenvironment modulator, enhances T cell-mediated tumor killing, and produces significant synergistic effects with inhibitors of PD-1, BRD and BIRC5. BTYNB can be used in relevant research on various malignant tumors including ovarian cancer, neuroblastoma, leukemia and melanoma.

For research use only. We do not sell to patients.

BTYNB Chemical Structure

CAS No. : 304456-62-0

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
250 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	Get quote
10 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

IC50: 5 μM (IMP1 c-Myc mRNA internation)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
HL-60	IC₅₀	21.56 μM Compound: 2; BTYNB	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 38382391]
K562	IC₅₀	6.76 μM Compound: 2; BTYNB	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 38382391]

In Vitro

BTYNB (20 μM; 24-36 h) significantly inhibits the migration and invasion of KYSE30 and TE1 ESCC cells in vitro^[2].
BTYNB (10 μM; 48 h) significantly increases apoptosis in KYSE30 and TE1 ESCC cells^[2].
BTYNB (0.38-24 µM; 72 h) combined with Mivebresib exhibits strong synergy in reducing BE(2)-C human neuroblastoma cell viability after 72 hours of treatment^[3].
BTYNB (7-21 μM; 24 h) induces mild apoptosis in human HL60 and K562 leukemic cells after 24 h of treatment, accompanied by significant upregulation of the pro-apoptotic gene BAK^[4].
BTYNB (7-21 μM; 24 h) induces S-phase cell cycle arrest in human K562 leukemic cells (with no effect on HL60 cells) after 24 h of treatment, accompanied by significant upregulation of the cell cycle arrest gene p21 in both cell lines^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Migration Assay ^[2]

Cell Line:	KYSE30, TE1 esophageal squamous cell carcinoma (ESCC) cells
Concentration:	20 μM
Incubation Time:	36 h (KYSE30 cells); 24 h (TE1 cells)
Result:	Reduced the relative cell area covered by invading KYSE30 cells to approximately 30% of control levels. Reduced the relative cell area covered by migrating KYSE30 cells to approximately 40% of control levels. Reduced the relative cell area covered by invading TE1 cells to approximately 20% of control levels. Reduced the relative cell area covered by migrating TE1 cells to approximately 10% of control levels.

In Vivo

Combination of BTYNB (40 mg/kg; i.p.; twice weekly) with anti-PD-1 blockade therapy significantly improves the median survival of mice, reduces tumor cell burden, and converts the tumor microenvironment to a more immunoresponsive state^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6NCrl mice (female, 6 weeks old, intraperitoneal injection of 5 × 10⁶ ID8/Trp53^-/- cells)^[1]
Dosage:	40 mg/kg (monotherapy); 40 mg/kg (combination with anti-PD-1 antibody 8 mg/kg)
Administration:	i.p.; twice weekly
Result:	Improved median survival by ~30% compared to the control group and by 15% compared to anti-PD-1 monotherapy when combined with anti-PD-1 antibody. Reduced tumor cell dominance in ascitic fluid to 67% when combined with anti-PD-1 antibody. Shifted tumor cells to an immune-responsive phenotype when combined with anti-PD-1 antibody. Increased immune cell accumulation in ascites (with a higher proportion of cytotoxic T cells than BTYNB monotherapy) when combined with anti-PD-1 antibody.

Molecular Weight

309.18

Formula

C₁₂H₉BrN₂OS

CAS No.

304456-62-0

Appearance

Solid

Color

White to light yellow

SMILES

O=C(C1=CC=CC=C1/N=C/C2=CC=C(S2)Br)N

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 62.5 mg/mL (202.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.2344 mL	16.1718 mL	32.3436 mL
5 mM	0.6469 mL	3.2344 mL	6.4687 mL
10 mM	0.3234 mL	1.6172 mL	3.2344 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (8.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.0%

Select Batch:

Data Sheet (281 KB) SDS (393 KB)

COA (250 KB) HNMR (265 KB) MS (72 KB)

Handling Instructions (2659 KB)

References

[1]. Bley N, et al. Inhibition of RNA-binding proteins enhances immunotherapy in ovarian cancer. Signal Transduct Target Ther. 2025;10(1):419. Published 2025 Dec 25.

[2]. Wang J J, et al. Elevated Expression of The RNA-Binding Protein IGF2BP1 Enhances The Mrna Stability and Translation E ciency of INHBA to Promote The Invasion and Migration of Esophageal Squamous Cancer Cells[J]. 2022.

[3]. Hagemann S, et al. IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression[J]. Molecular cancer, 2023, 22(1): 88.

[4]. Jamal A, et al. BTYNB, an inhibitor of RNA binding protein IGF2BP1 reduces proliferation and induces differentiation of leukemic cancer cells. Saudi J Biol Sci. 2023;30(3):103569.

[5]. Mahapatra L, et al. A Novel IMP1 Inhibitor, BTYNB, Targets c-Myc and Inhibits Melanoma and Ovarian Cancer Cell Proliferation. Transl Oncol. 2017;10(5):818-827. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.2344 mL	16.1718 mL	32.3436 mL	80.8590 mL
	5 mM	0.6469 mL	3.2344 mL	6.4687 mL	16.1718 mL
	10 mM	0.3234 mL	1.6172 mL	3.2344 mL	8.0859 mL
	15 mM	0.2156 mL	1.0781 mL	2.1562 mL	5.3906 mL
	20 mM	0.1617 mL	0.8086 mL	1.6172 mL	4.0430 mL
	25 mM	0.1294 mL	0.6469 mL	1.2937 mL	3.2344 mL
	30 mM	0.1078 mL	0.5391 mL	1.0781 mL	2.6953 mL
	40 mM	0.0809 mL	0.4043 mL	0.8086 mL	2.0215 mL
	50 mM	0.0647 mL	0.3234 mL	0.6469 mL	1.6172 mL
	60 mM	0.0539 mL	0.2695 mL	0.5391 mL	1.3477 mL
	80 mM	0.0404 mL	0.2021 mL	0.4043 mL	1.0107 mL
	100 mM	0.0323 mL	0.1617 mL	0.3234 mL	0.8086 mL

BTYNB Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

BTYNB

Customer Review

BTYNB Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

BTYNB Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

BTYNB Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report